Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Usman Waheed

Trauma Surgery Laurel, MD Medical Doctor

NPI 1619187408 CMS profile 73124

14201 Laurel Park Dr, Ste 225, Laurel, MD 20707

Open in the dashboard

General payments

$14,805

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Usman Waheed of Laurel, MD is reported in the CMS Open Payments database as having received $14,805 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Trauma Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,574 37
2024 General $217 11
2023 General $1,466 19
2022 General $5,294 21
2021 General $262 8
2020 General $139 9
2019 General $4,853 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Usman Waheed
  • Trauma Surgery median
  • Middle half of Trauma Surgery
  • National median

In program year 2025, general payments to Usman Waheed were reported at $2,574. Among 762 Trauma Surgery profiles paid that year, the median was $280 and the middle half received between $87 and $1,585.

Show as a table
Year Usman Waheed Trauma Surgery median Middle half National median
2019 $4,853 $153 $56–$644 $163
2020 $139 $123 $39–$342 $114
2021 $262 $142 $45–$556 $132
2022 $5,294 $172 $59–$732 $149
2023 $1,466 $213 $83–$1,200 $160
2024 $217 $237 $86–$1,280 $164
2025 $2,574 $280 $87–$1,585 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $5,867 25 payments
  2. Acell, Inc. $3,909 15 payments
  3. Smith+Nephew, Inc. $2,483 31 payments
  4. KCI USA, Inc $932 2 payments
  5. Organogenesis Inc. $509 21 payments
  6. Aroa Biosurgery Incorporated $394 1 payment
  7. Musculoskeletal Transplant Foundation Inc. $215 4 payments
  8. Solventum Corporation $69 3 payments
  9. Janssen Pharmaceuticals, Inc $66 4 payments
  10. Kerecis Limited $63 3 payments
  11. Other $299 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,800 2 payments
  2. Food and Beverage $3,636 107 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,440 3 payments
  4. Travel and Lodging $2,530 11 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,400 1 payment
Products named General payments · program years 2019–2025
  1. Integra Recon-Skin And Wound $3,809 13 payments
  2. Integra Recon-Skin And Wound $3,809 13 payments
  3. NEURAGEN $3,436 5 payments
  4. PRIMATRIX $2,663 17 payments
  5. PICO $1,996 8 payments
  6. COLLAGENASE SANTYL $1,839 22 payments
  7. Versajet $1,526 7 payments
  8. GRAFIX $1,526 7 payments
  9. Cytal $1,400 1 payment
  10. VAC VERAFLO $932 2 payments
  11. Other $4,824 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

33

Median for General Surgery: 59

Drug cost

$13,296

Median for General Surgery: $393

Branded share of claims

100%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 22 $13,275
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 11 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$473,110

Medicare's payments for the services billed

Medicare patients

343

Average age 77

Services billed

4,042

200 women, 143 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 57%
Depression 55%
Alzheimer's or dementia 53%
Chronic kidney disease 52%
Heart failure 48%
Ischemic heart disease 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Trauma Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record